Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer

Jun Miyazaki, Shiro Hinotsu, Naoki Ishizuka, Seiji Naito, Seiichiro Ozono, Hideyuki Akaza, Hiroyuki Nishiyama

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: The aim of the study was to investigate the factor of adverse reactions related to compliance with Mycobacterium bovis bacillus Calmette-Gué rin maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer. Methods: This study was a post hoc analysis using the database of a randomized controlled trial that examined the efficacy of bacillus Calmette-Gué rin (Connaught strain) maintenance therapy. Among the 42 patients assigned to the bacillus Calmette-Gué rin maintenance therapy group, six patients dropped out or withdrew consent before the bacillus Calmette- Gué rin maintenance therapy. The adverse reactions and clinical backgrounds of the remaining 36 patients who underwent bacillus Calmette-Gué rin maintenance therapy were compared between the two groups: the patients who completed the bacillus Calmette-Gué rin maintenance therapy (the Completed group), and those who discontinued the bacillus Calmette- Gué rin maintenance therapy (the Discontinued group). Results: Of the 36 patients who underwent bacillus Calmette-Gué rin maintenance therapy, 15 (41.7%) were in the Completed group and 21 (58.3%) were in the Discontinued group. Local adverse reactions (≥G2) were observed during maintenance therapy in 86.7% of the Completed group and 95.2% of the Discontinued group. As for adverse reactions during the induction therapy (bacillus Calmette-Gué rin induction therapy), the frequencies of gross hematuria and systemic adverse reactions (any grade) tended to be higher in the Discontinued group than in the Completed group, although not significantly so. In the Cochran-Armitage trend test, the linear T trend (i.e. the trend in the risk of an increased rate of discontinuation according to gross hematuria and systemic adverse reactions with bacillus Calmette-Gué rin induction therapy) was statistically significant (P = 0.0179). Conclusions: Most patients who completed bacillus Calmette-Gué rin maintenance therapy experienced local adverse reactions (≥G2) during the maintenance therapy. Gross hematuria and systemic adverse reactions during bacillus Calmette-Gué rin induction therapy might be related to the discontinuation of bacillus Calmette-Gué rin maintenance therapy because of severe adverse reactions.

Original languageEnglish
Pages (from-to)827-834
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume43
Issue number8
DOIs
Publication statusPublished - Aug 2013
Externally publishedYes

Fingerprint

Mycobacterium bovis
Urinary Bladder Neoplasms
Bacillus
Therapeutics
Hematuria
Group Psychotherapy
Randomized Controlled Trials
Databases

Keywords

  • Adverse reactions
  • Bacillus Calmette-guérin
  • Maintenance therapy
  • Non-muscle-invasive bladder cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer. / Miyazaki, Jun; Hinotsu, Shiro; Ishizuka, Naoki; Naito, Seiji; Ozono, Seiichiro; Akaza, Hideyuki; Nishiyama, Hiroyuki.

In: Japanese Journal of Clinical Oncology, Vol. 43, No. 8, 08.2013, p. 827-834.

Research output: Contribution to journalArticle

Miyazaki, Jun ; Hinotsu, Shiro ; Ishizuka, Naoki ; Naito, Seiji ; Ozono, Seiichiro ; Akaza, Hideyuki ; Nishiyama, Hiroyuki. / Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer. In: Japanese Journal of Clinical Oncology. 2013 ; Vol. 43, No. 8. pp. 827-834.
@article{ff8b4955bea740c4944c63dd24883208,
title = "Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer",
abstract = "Objective: The aim of the study was to investigate the factor of adverse reactions related to compliance with Mycobacterium bovis bacillus Calmette-Gu{\'e} rin maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer. Methods: This study was a post hoc analysis using the database of a randomized controlled trial that examined the efficacy of bacillus Calmette-Gu{\'e} rin (Connaught strain) maintenance therapy. Among the 42 patients assigned to the bacillus Calmette-Gu{\'e} rin maintenance therapy group, six patients dropped out or withdrew consent before the bacillus Calmette- Gu{\'e} rin maintenance therapy. The adverse reactions and clinical backgrounds of the remaining 36 patients who underwent bacillus Calmette-Gu{\'e} rin maintenance therapy were compared between the two groups: the patients who completed the bacillus Calmette-Gu{\'e} rin maintenance therapy (the Completed group), and those who discontinued the bacillus Calmette- Gu{\'e} rin maintenance therapy (the Discontinued group). Results: Of the 36 patients who underwent bacillus Calmette-Gu{\'e} rin maintenance therapy, 15 (41.7{\%}) were in the Completed group and 21 (58.3{\%}) were in the Discontinued group. Local adverse reactions (≥G2) were observed during maintenance therapy in 86.7{\%} of the Completed group and 95.2{\%} of the Discontinued group. As for adverse reactions during the induction therapy (bacillus Calmette-Gu{\'e} rin induction therapy), the frequencies of gross hematuria and systemic adverse reactions (any grade) tended to be higher in the Discontinued group than in the Completed group, although not significantly so. In the Cochran-Armitage trend test, the linear T trend (i.e. the trend in the risk of an increased rate of discontinuation according to gross hematuria and systemic adverse reactions with bacillus Calmette-Gu{\'e} rin induction therapy) was statistically significant (P = 0.0179). Conclusions: Most patients who completed bacillus Calmette-Gu{\'e} rin maintenance therapy experienced local adverse reactions (≥G2) during the maintenance therapy. Gross hematuria and systemic adverse reactions during bacillus Calmette-Gu{\'e} rin induction therapy might be related to the discontinuation of bacillus Calmette-Gu{\'e} rin maintenance therapy because of severe adverse reactions.",
keywords = "Adverse reactions, Bacillus Calmette-gu{\'e}rin, Maintenance therapy, Non-muscle-invasive bladder cancer",
author = "Jun Miyazaki and Shiro Hinotsu and Naoki Ishizuka and Seiji Naito and Seiichiro Ozono and Hideyuki Akaza and Hiroyuki Nishiyama",
year = "2013",
month = "8",
doi = "10.1093/jjco/hyt086",
language = "English",
volume = "43",
pages = "827--834",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer

AU - Miyazaki, Jun

AU - Hinotsu, Shiro

AU - Ishizuka, Naoki

AU - Naito, Seiji

AU - Ozono, Seiichiro

AU - Akaza, Hideyuki

AU - Nishiyama, Hiroyuki

PY - 2013/8

Y1 - 2013/8

N2 - Objective: The aim of the study was to investigate the factor of adverse reactions related to compliance with Mycobacterium bovis bacillus Calmette-Gué rin maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer. Methods: This study was a post hoc analysis using the database of a randomized controlled trial that examined the efficacy of bacillus Calmette-Gué rin (Connaught strain) maintenance therapy. Among the 42 patients assigned to the bacillus Calmette-Gué rin maintenance therapy group, six patients dropped out or withdrew consent before the bacillus Calmette- Gué rin maintenance therapy. The adverse reactions and clinical backgrounds of the remaining 36 patients who underwent bacillus Calmette-Gué rin maintenance therapy were compared between the two groups: the patients who completed the bacillus Calmette-Gué rin maintenance therapy (the Completed group), and those who discontinued the bacillus Calmette- Gué rin maintenance therapy (the Discontinued group). Results: Of the 36 patients who underwent bacillus Calmette-Gué rin maintenance therapy, 15 (41.7%) were in the Completed group and 21 (58.3%) were in the Discontinued group. Local adverse reactions (≥G2) were observed during maintenance therapy in 86.7% of the Completed group and 95.2% of the Discontinued group. As for adverse reactions during the induction therapy (bacillus Calmette-Gué rin induction therapy), the frequencies of gross hematuria and systemic adverse reactions (any grade) tended to be higher in the Discontinued group than in the Completed group, although not significantly so. In the Cochran-Armitage trend test, the linear T trend (i.e. the trend in the risk of an increased rate of discontinuation according to gross hematuria and systemic adverse reactions with bacillus Calmette-Gué rin induction therapy) was statistically significant (P = 0.0179). Conclusions: Most patients who completed bacillus Calmette-Gué rin maintenance therapy experienced local adverse reactions (≥G2) during the maintenance therapy. Gross hematuria and systemic adverse reactions during bacillus Calmette-Gué rin induction therapy might be related to the discontinuation of bacillus Calmette-Gué rin maintenance therapy because of severe adverse reactions.

AB - Objective: The aim of the study was to investigate the factor of adverse reactions related to compliance with Mycobacterium bovis bacillus Calmette-Gué rin maintenance therapy in patients with high-risk non-muscle-invasive bladder cancer. Methods: This study was a post hoc analysis using the database of a randomized controlled trial that examined the efficacy of bacillus Calmette-Gué rin (Connaught strain) maintenance therapy. Among the 42 patients assigned to the bacillus Calmette-Gué rin maintenance therapy group, six patients dropped out or withdrew consent before the bacillus Calmette- Gué rin maintenance therapy. The adverse reactions and clinical backgrounds of the remaining 36 patients who underwent bacillus Calmette-Gué rin maintenance therapy were compared between the two groups: the patients who completed the bacillus Calmette-Gué rin maintenance therapy (the Completed group), and those who discontinued the bacillus Calmette- Gué rin maintenance therapy (the Discontinued group). Results: Of the 36 patients who underwent bacillus Calmette-Gué rin maintenance therapy, 15 (41.7%) were in the Completed group and 21 (58.3%) were in the Discontinued group. Local adverse reactions (≥G2) were observed during maintenance therapy in 86.7% of the Completed group and 95.2% of the Discontinued group. As for adverse reactions during the induction therapy (bacillus Calmette-Gué rin induction therapy), the frequencies of gross hematuria and systemic adverse reactions (any grade) tended to be higher in the Discontinued group than in the Completed group, although not significantly so. In the Cochran-Armitage trend test, the linear T trend (i.e. the trend in the risk of an increased rate of discontinuation according to gross hematuria and systemic adverse reactions with bacillus Calmette-Gué rin induction therapy) was statistically significant (P = 0.0179). Conclusions: Most patients who completed bacillus Calmette-Gué rin maintenance therapy experienced local adverse reactions (≥G2) during the maintenance therapy. Gross hematuria and systemic adverse reactions during bacillus Calmette-Gué rin induction therapy might be related to the discontinuation of bacillus Calmette-Gué rin maintenance therapy because of severe adverse reactions.

KW - Adverse reactions

KW - Bacillus Calmette-guérin

KW - Maintenance therapy

KW - Non-muscle-invasive bladder cancer

UR - http://www.scopus.com/inward/record.url?scp=84881095407&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881095407&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyt086

DO - 10.1093/jjco/hyt086

M3 - Article

C2 - 23858038

AN - SCOPUS:84881095407

VL - 43

SP - 827

EP - 834

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 8

ER -